patent.fyi
Applications  /  US 2026/0354757
United States Patent Application Publication

US 2026/0354757 A1

Published
Nov 12, 2026
Filed
Dec 16, 2023
Earliest date on the face
Dec 16, 2022
Classification
A61B 5/4848
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Chromatographic measurement of drug concentration

What ifWhat if timed plasma samples go to a liquid chromatograph with a tandem mass detector instead of an electrochemical aptamer-based sensor?
Claim language“an electrochemical aptamer-based sensor”

Each plasma sample receives an isotope-labeled internal reference and undergoes protein precipitation before injection. The instrument separates the drug on a chromatographic column and converts the drug-to-reference peak area ratio to a concentration using a calibration curve.

1.1Optical measurement by antibody competition

What ifWhat if an optical immunoassay measures drug concentration instead of an electrochemical aptamer-based sensor?
Claim language“an electrochemical aptamer-based sensor”

Drug in each timed fluid sample competes with a fluorescent drug tracer for a limited number of antibody binding sites. An optical reader measures fluorescence polarization, and a calibration curve converts the reading to drug concentration.

1.2Transfer only the peak event

What ifWhat if the receiving computer gets one peak-event timestamp per dose instead of output values or derivatives thereof?
Claim language“output values or derivatives thereof”

An onboard controller tracks the largest filtered sensor reading and stores its timestamp. After a sustained decline confirms the peak, the controller transmits only the stored timestamp, and the receiving computer subtracts the dose timestamp to find the time to peak.

1.3Peak calculation from dose records

What ifWhat if the computer calculates a predicted peak from the dose record and stored pharmacokinetic parameters without using the sensor series?
Claim language“using the series of output values”

The computer supplies the oral dose and dose time to a one-compartment model with stored apparent clearance, apparent volume of distribution, and a first-order absorption rate. It evaluates the predicted concentration curve and returns its maximum and the elapsed time at that maximum.

1.4Six-hour measurement intervals

What ifWhat if the receiver obtains one sensor value every six hours for a drug with a broad peak after extended-release dosing?
Claim language“less than about 4 hours, 3 hours, 2 hours, or 1 hour”

The receiver records a calibrated concentration at each scheduled transmission for 48 hours after dosing. A fitted absorption and elimination curve uses the rising and falling samples to estimate the peak and its timing between transmissions.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Drug monitoring in an aquaculture tank

An electrochemical aptamer sensor sits in a flow cell fed by a recirculating aquaculture tank after a waterborne drug dose. A pump draws water downstream of the tank mixing zone through a mesh strainer and returns it to the tank. A controller converts timestamped sensor readings to concentrations using a calibration prepared in tank water and integrates the concentration series to calculate exposure during the treatment period.

Component substitution

Competitive antibody sensor for plasma monitoring

A competitive electrochemical immunoassay replaces the aptamer sensor and uses drug-specific antibody-coated magnetic beads and an enzyme-labeled drug tracer. Successive plasma aliquots enter a flow cell, where drug in each aliquot competes with the tracer for binding sites on fresh beads. A magnet holds the beads during washing, and an electrode measures the electroactive product generated by the retained tracer after substrate addition. A processor applies a calibration curve and integrates the resulting concentration series to calculate exposure over the sampling window.

Parameter or scale variation

Four depth channels for tissue exposure

A fixture holds four independently wired aptamer-coated working electrodes with exposed tips at depths of 1, 2, 3, and 4 millimeters below the skin surface. Each electrode contacts interstitial fluid, and a multiplexed potentiostat reads the four channels against a shared reference electrode once every 30 seconds. Software applies a separate calibration to each channel and calculates the area under each concentration curve during the first 2 hours after dosing.

Combination with existing systems

Infusion pump records aligned with sensor data

An infusion pump exports timestamped drug delivery rates and start, pause, and stop events to the workstation that receives measurements from an interstitial fluid aptamer sensor. The workstation aligns both streams to a common clock and uses the recorded end of infusion to define the post-infusion analysis window. Software fits a straight line to the logarithms of calibrated concentrations within a selected terminal segment and calculates the terminal half-life from the negative slope.

Automated or data-driven variant

Model-based estimation of drug clearance

Software receives timestamped concentrations from an electrochemical aptamer sensor and a separate record of intravenous dose and delivery times. A one-compartment model represents plasma drug concentration, and a first-order exchange term represents the lag between plasma and interstitial fluid. A Bayesian filter updates the estimates of systemic clearance and interstitial lag as readings arrive and reports an uncertainty interval for each estimate.

Reference channel correction for exposure estimates

Two adjacent working electrodes contact the same interstitial fluid, with a drug-binding aptamer on one electrode and a nonbinding oligonucleotide on the other. Both oligonucleotides carry the same redox reporter, and the potentiostat interrogates the channels with the same waveform. Software subtracts a scaled change in reference current from the drug-channel current using a factor measured during drug-free baseline testing. It converts the corrected series to concentration and interpolates threshold crossing times to calculate the total duration above a specified concentration.

Specific version of a part

Gold electrode with tethered aptamer

A gold working electrode carries a thiol-tethered drug-binding aptamer with a redox tag at its free end. Drug binding changes electron transfer between the tag and the electrode, and square-wave voltammetry measures the resulting current change.

Timestamped current readings over cable

A potentiostat digitizes the redox peak current after each voltage scan and pairs the value with a clock timestamp. A computer receives the records over a serial cable and stores them in timestamp order.

Quadratic fit around the peak

Software converts sensor currents to concentrations, finds the highest observed concentration, and fits a quadratic to that sample and its two immediate neighbors. When the fitted curve opens downward and its vertex lies between the neighboring timestamps, the vertex gives the estimated peak concentration and time.

Fixed five-minute acquisition

A hardware timer triggers one voltage scan every five minutes. The receiver records each output with the scan timestamp as soon as the scan ends.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2007/0239416 A1
Published
Oct 11, 2007
Filed
Mar 23, 2007
Class
G06G 7/48
Document BUS 2016/0278638 A1
Published
Sep 29, 2016
Filed
Mar 26, 2015
Class
A61B 5/002
Claim 1
Document A
Document B
1.1contacting a fluid of the subject with an electrochemical aptamer-based sensor capable of detecting the drug,
The system includes a substrate including a sensor, the sensor comprising aptamer conjugates, wherein the sensor is configured to obtain one or more measurements related to at least one analyte in interstitial fluid, and wherein the substrate is configured for implantation into skin; and a reader device, wherein the reader device is configured to detect the analyte in interstitial fluid via interaction with the substrate.
B · US 2016/0278638 A1 · ¶ 5
1.2receiving a series of output values or derivatives thereof of the electrochemical aptamer-based sensor over a period of time, and
The reader 680 can thus be operated to intermittently power the implanted electrochemical sensor 630 so as to obtain a time series of amperometric current measurements.
B · US 2016/0278638 A1 · ¶ 143
1.3using the series of output values or derivatives thereof to identify the pharmacokinetic feature,
When investigating pharmacokinetics in humans, data on the pharmacokinetics, such as in-blood drug concentration or in-urine excretion amount obtained from a clinical trial, is analyzed using statistics. After that, the pharmacokinetics is investigated based on this analysis result.
A · US 2007/0239416 A1 · ¶ 4
1.4wherein the output values or derivatives thereof are received at a time interval or an averaged time interval of less than about 4 hours, 3 hours, 2 hours, or 1 hour.

An empty cell means only that no passage was reproduced there.

Statements in these documents
In general, the data on the pharmacokinetics exhibits large variations between individuals and inside an individual.
A · US 2007/0239416 A1 · ¶ 6
The present invention relates to a pharmacokinetic analysis system and a method of the pharmacokinetic analysis for analyzing transition of in-blood drug concentration of an individual in such a manner that the influence of genetic polymorphism is taken into consideration.
A · US 2007/0239416 A1 · ¶ 2
For most people, the blood tests are infrequent, and an abnormal analyte level indicative of a medical condition may not be identified for some time after the blood work is performed.
B · US 2016/0278638 A1 · ¶ 3
The detected optical change can be used to determine the presence/absence of an analyte or the concentration of an analyte.
B · US 2016/0278638 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0354757 A1, claim 1, first published 2026-11-19T03:31:31-05:00, https://patent.fyi/US20260354757/, SHA-256 3c57748428b44623d27fa152ade1a2e8c43193e424f773c49f42da5edf1ea163
First published
Permanent addresshttps://patent.fyi/US20260354757/
Content fingerprint (SHA-256)3c57748428b44623d27fa152ade1a2e8c43193e424f773c49f42da5edf1ea163
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi